AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 05, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and...
CareMed Has Been Selected as a National Specialty Pharmacy Partner for Lecanemab-irmb (Leqembi®)
October 29, 2024 07:30 ET
|
CareMed Specialty Pharmacy
NEW HYDE PARK, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- CareMed, a leading independent Specialty Pharmacy, has been selected by Eisai to be in the pharmacy network for Leqembi® (lecanemab-irmb)....
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
September 17, 2024 07:00 ET
|
AC Immune SA
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical...
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
July 16, 2024 07:00 ET
|
AC Immune SA
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s...
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
June 27, 2024 08:00 ET
|
INmune Bio, Inc.
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party,...
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024 06:05 ET
|
AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024 06:00 ET
|
AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...
Unlocking the Secrets to a Sharper Mind and Healthier Cells
April 17, 2024 09:00 ET
|
Return Healthy
St. George, Utah, April 17, 2024 (GLOBE NEWSWIRE) -- In an era of rising health concerns, particularly those affecting cognitive functions, Return Healthy reveals its groundbreaking Cell...
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
March 14, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in...